A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

This study is testing an experimental drug called MDNA11, designed to boost your immune system's ability to identify and fight advanced cancer. Researchers want to see if this drug, either alone or paired with an immunotherapy medicine, is safe and effective for people with various types of solid tumors.

This trial is for adults (18+) who have advanced solid tumors that have spread. You must be generally active and have stable organ function, and you cannot have received recent cancer treatments or be currently enrolled in another clinical trial.

Participants will receive the study treatment while doctors closely monitor their health and reactions. The team will perform regular check-ups, including blood tests and scans, to see how the cancer responds to the treatment.

The study is currently recruiting patients at medical centers in San Diego, San Francisco, and Santa Monica, California. You should talk to your oncologist to see if your specific diagnosis matches the study requirements.